Skip to main content

AI Model FastGlioma Can Detect Glioma Infiltration During Surgery

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 21, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Nov. 21, 2024 -- The artificial intelligence (AI) model FastGlioma can detect glioma infiltration during surgery, according to a study published online Nov. 13 in Nature.

Akhil Kondepudi, from the University of Michigan in Ann Arbor, and colleagues presented a visual foundation model for fast and accurate detection of glioma infiltration in fresh, unprocessed surgical tissue. FastGlioma was pretrained using large-scale self-supervision on rapid, label-free optical microscopy, using about 4 million images, and was then fine-tuned to output a normalized score indicating the degree of tumor infiltration. FastGlioma was then tested in a prospective, multicenter international testing cohort of 220 patients with diffuse glioma.

The researchers found that FastGlioma was able to detect and quantify the degree of tumor infiltration (average area under the curve, 92.1 ± 0.9 percent). For detecting tumor infiltration during surgery, FastGlioma outperformed image-guided and fluorescence-guided adjuncts by a wide margin in a head-to-head prospective study involving 129 patients. Across diverse patient demographics, medical centers, and diffuse glioma molecular subtypes, the performance of FastGlioma remained high. Zero-shot generalization was seen for other adult and pediatric brain tumor diagnoses with FastGlioma.

"This model is an innovative departure from existing surgical techniques by rapidly identifying tumor infiltration at microscopic resolution using AI, greatly reducing the risk of missing residual tumor in the area where a glioma is resected," co-senior author Shawn Hervey-Jumper, M.D., from the University of California, San Francisco, said in a statement. "The development of FastGlioma can minimize the reliance on radiographic imaging, contrast enhancement, or fluorescent labels to achieve maximal tumor removal."

Several authors are shareholders in Invenio Imaging, which was used in the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections

WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...

AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...

AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors

TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.